Neoadjuvant strategies in resectable carcinoma esophagus: a meta-analysis of randomized trials
Background The survival benefit of neoadjuvant therapy in resectable carcinoma esophagus
has been elucidated. We performed a meta-analysis in light of new studies and long-term …
has been elucidated. We performed a meta-analysis in light of new studies and long-term …
Adjuvant concurrent chemoradiation using intensity-modulated radiotherapy and simultaneous integrated boost for resected high-risk adenocarcinoma of the distal …
BP Yaremko, DA Palma, AL Erickson, G Pierce… - Radiation …, 2013 - Springer
Purpose Multimodality therapy leads to improved outcomes for adenocarcinoma of the distal
esophagus and gastroesophageal junction (GEJ) over surgery alone. At our institution …
esophagus and gastroesophageal junction (GEJ) over surgery alone. At our institution …
Health-related quality of life in patients with locally advanced gastric cancer undergoing perioperative or postoperative adjuvant S-1 plus oxaliplatin with D2 …
J Yu, Z Wang, Z Li, Y Liu, Y Fan, J Di, M Cui… - Frontiers in …, 2022 - frontiersin.org
Background Some high-quality clinical trials have proven the efficacy and safety of
perioperative and postoperative S-1 with oxaliplatin (peri-SOX and post-SOX) for patients …
perioperative and postoperative S-1 with oxaliplatin (peri-SOX and post-SOX) for patients …
When randomized trials and observational data disagree: The case of preoperative versus postoperative chemoradiotherapy for esophageal cancer.
DA Palma, GB Rodrigues… - Cancer (0008543X), 2013 - search.ebscohost.com
When randomized trials and observational data disagree: The case of preoperative versus
postoperative chemoradiotherapy for esop Page 1 When Randomized Trials and Observational …
postoperative chemoradiotherapy for esop Page 1 When Randomized Trials and Observational …